Eleven Biotherapeutics, Inc. was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $1.02–$1.58 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one positive estimate revision in the past two months. Its Zacks Consensus Estimate for the current quarter has also revised upward over the same time frame. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Eleven Biotherapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Eleven Biotherapeutics, Inc. Price and Consensus
A better ranked stock worth considering in the Medical - Biomedical and Genetics industry is Horizon Pharma Public Limited Company (HZNP - Free Report) which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is EBIO going up? Or down? Predict to see what others think: Up or Down
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>